These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
328 related items for PubMed ID: 16773629
21. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. Freiha F, Reese J, Torti FM. J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644 [Abstract] [Full Text] [Related]
22. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B, Orefici F. Cancer; 2004 Dec 01; 101(11):2540-8. PubMed ID: 15481058 [Abstract] [Full Text] [Related]
23. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP. J Urol; 2006 Dec 01; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118 [Abstract] [Full Text] [Related]
24. The D allele of angiotensin-converting enzyme polymorphism as a predictor of renal function decline over 4 years in an apparently healthy Chinese population aged 60 and older. Lee YT, Chiu HC, Su HM, Voon WC, Lin TH, Lai WT, Sheu SH. J Am Geriatr Soc; 2008 Apr 01; 56(4):718-23. PubMed ID: 18284535 [Abstract] [Full Text] [Related]
25. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline. Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR, Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group. Can J Urol; 2002 Oct 01; 9(5):1625-33. PubMed ID: 12431323 [Abstract] [Full Text] [Related]
26. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy. Lehmann J, Retz M, Stöckle M. World J Urol; 2002 Aug 01; 20(3):144-50. PubMed ID: 12196897 [Abstract] [Full Text] [Related]
27. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Spruill WJ, Wade WE, Cobb HH. Am J Geriatr Pharmacother; 2008 Aug 01; 6(3):153-60. PubMed ID: 18775390 [Abstract] [Full Text] [Related]
28. Evaluation of creatinine-based estimates of glomerular filtration rate in a large cohort of living kidney donors. Issa N, Meyer KH, Arrigain S, Choure G, Fatica RA, Nurko S, Stephany BR, Poggio ED. Transplantation; 2008 Jul 27; 86(2):223-30. PubMed ID: 18645483 [Abstract] [Full Text] [Related]
29. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N. Urology; 2004 Sep 27; 64(3):488-93. PubMed ID: 15351577 [Abstract] [Full Text] [Related]
33. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors. Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N. J Urol; 1996 Jun 27; 155(6):1897-902. PubMed ID: 8618282 [Abstract] [Full Text] [Related]